In Vitro Activity of Caspofungin (MK-0991) against Candida albicans Clinical Isolates Displaying Different Mechanisms of Azole Resistance

Open Access

1 June 2002

journal article
Published by American Society for Microbiology in Journal of Clinical Microbiology

Vol. 40 (6) , 2228-2230
https://doi.org/10.1128/jcm.40.6.2228-2230.2002

Abstract

Caspofungin inhibits the synthesis of 1,3-β-d-glucan, a key step in fungal cell wall biosynthesis. Here we report on its potent in vitro activity (MIC at which 90% of the isolates tested are inhibited = 1 μg per ml of RPMI medium) against 32 Candida albicans fluconazole-susceptible and -resistant clinical isolates irrespective of the underlying resistance mechanism (alterations in ERG11 and/or upregulation of MDR and CDR genes encoding efflux pumps) and provide further evidence that caspofungin is not a substrate for multidrug transporters.

Keywords

This publication has 13 references indexed in Scilit:

Prevalence of Molecular Mechanisms of Resistance to Azole Antifungal Agents in Candida albicans Strains Displaying High-Level Fluconazole Resistance Isolated from Human Immunodeficiency Virus-Infected Patients
Antimicrobial Agents and Chemotherapy, 2001
Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis
Journal of Antimicrobial Chemotherapy, 2000
In Vitro Activity of the New Echinocandin Antifungal, MK-0991, against Common and Uncommon Clinical Isolates of Candida Species
European Journal of Clinical Microbiology & Infectious Diseases, 1999
Activity of MK-0991 (l-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
Diagnostic Microbiology and Infectious Disease, 1998
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
Clinical Microbiology Reviews, 1998
In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
Antimicrobial Agents and Chemotherapy, 1997
In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species
Antimicrobial Agents and Chemotherapy, 1997
In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions.
1997
Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene
Microbiology, 1997
In vitrogrowth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistantCandidaisolates: influence of assay conditions
Medical Mycology, 1997